Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 54 citing articles:

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Wah‐Kheong Chan, Kee Huat Chuah, Ruveena Bhavani Rajaram, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 3, pp. 197-213
Open Access | Times Cited: 265
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong Li, Junyan Zou, Wei Ran, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 149
Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD
Kathleen Clare, John Dillon, Paul Brennan
Journal of Clinical and Translational Hepatology (2022) Vol. 10, Iss. 5, pp. 939-946
Open Access | Times Cited: 74
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
Xiaolong Qi, Jie Li, Cyrielle Caussy, et al.
Hepatology (2024)
Open Access | Times Cited: 18
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, et al.
Hepatology International (2025)
Closed Access | Times Cited: 4
Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study
Ibrahim Ayada, Laurens A. van Kleef, Huai Zhang, et al.
EBioMedicine (2022) Vol. 87, pp. 104392-104392
Open Access | Times Cited: 62
Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
Gashaw Hassen, Abhishek Singh, Gizeshwork Belete, et al.
Cureus (2022)
Open Access | Times Cited: 40
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
Anders Mellemkjær, Mikkel Breinholt Kjær, David Haldrup, et al.
European Journal of Internal Medicine (2023) Vol. 122, pp. 28-34
Open Access | Times Cited: 36
A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
Shiqin Zhang, Xiaoling Ren, Bingzheng Zhang, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1859-1859
Open Access | Times Cited: 12
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
Xin Ding, Xu He, Bulang Tang, et al.
Chinese Medicine (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 10
What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Marcin Kosmalski, Rafał Frankowski, Sylwia Ziółkowska, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1852-1852
Open Access | Times Cited: 22
Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
Branka Filipović, Marija Marjanovic-Haljilji, Dragana Mijač, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 11, pp. 9132-9148
Open Access | Times Cited: 17
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Qingfu Dong, Haolin Bao, Jiangang Wang, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 16
Mitochondrial Cholesterol Metabolites in a Bile Acid Synthetic Pathway Drive Nonalcoholic Fatty Liver Disease: A Revised “Two-Hit” Hypothesis
Genta Kakiyama, Daniel Rodríguez‐Agudo, William M. Pandak
Cells (2023) Vol. 12, Iss. 10, pp. 1434-1434
Open Access | Times Cited: 13
Metabolic dysfunction-associated fatty liver disease increases risk of chronic kidney disease: a systematic review and meta-analysis
Jianghua Zhou, Dan‐Qin Sun, Giovanni Targher, et al.
eGastroenterology (2023) Vol. 1, Iss. 1, pp. e100005-e100005
Open Access | Times Cited: 13
Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM
Szu‐Yuan Wu, Wan‐Ming Chen, Ming‐Feng Chiang, et al.
Liver International (2023) Vol. 43, Iss. 10, pp. 2232-2244
Closed Access | Times Cited: 11
Mitochondria-derived peptide SHLP2 regulates energy homeostasis through the activation of hypothalamic neurons
Seul Ki Kim, Trung Le Tran, Cherl NamKoong, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 11
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal
Nature Reviews Drug Discovery (2024)
Closed Access | Times Cited: 4
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
Wenjing Geng, Wanying Liao, Xinyuan Cao, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 393-393
Open Access
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment
Marios Zisis, Maria Chondrogianni, Θεόδωρος Ανδρουτσάκος, et al.
Biomolecules (2025) Vol. 15, Iss. 3, pp. 324-324
Open Access
Research Progress of the Prevention and Treatment of Metabolic Associated Fatty Liver Disease as a Complication Disease of Endocrine Therapy for Breast Cancer
胜鹏 覃
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 581-590
Closed Access
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
В. Т. Ивашкин, О. М. Драпкина, M. V. Maevskaya, et al.
Russian Journal of Gastroenterology Hepatology Coloproctology (2025) Vol. 35, Iss. 1, pp. 94-152
Open Access
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, et al.
Medicina (2023) Vol. 59, Iss. 10, pp. 1789-1789
Open Access | Times Cited: 9
Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Angeliki Katsarou, Georgios Tsioulos, Eva Kassi, et al.
HORMONES (2024) Vol. 23, Iss. 4, pp. 621-636
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top